Acetylsalicylic acid pretreatment, concomitant heparin therapy and the risk of early intracranial hemorrhage following systemic thrombolysis for acute ischemic stroke

Cerebrovasc Dis. 2003;16(3):183-90. doi: 10.1159/000071114.

Abstract

Background: The risk of intracerebral hemorrhage in systemic thrombolysis for acute ischemic stroke after acetylsalicylic acid (ASA) pretreatment or with subsequent heparin is controversially discussed.

Methods: 300 consecutive stroke patients were treated with recombinant tissue-type plasminogen activator (rt-PA) in a prospective open study (92 pretreated with ASA, 202 ASA nonusers) with 3 months of follow-up. After thrombolysis, 122 patients received low-dose, 153 patients high-dose heparin.

Results: Logistic regression analysis showed no relationship of hemorrhagic complications within the first 48 h to ASA pretreatment (p = 0.15), or heparin application (p = 0.38), but dependency on stroke severity (NIHSS) at baseline (p = 0.01).

Conclusion: ASA pretreatment does not increase the risk of symptomatic bleeding after systemic thrombolysis with rt-PA, even if thrombolysis is followed by anticoagulation.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase IV

MeSH terms

  • Acute Disease
  • Aged
  • Aspirin / administration & dosage
  • Aspirin / adverse effects*
  • Aspirin / therapeutic use*
  • Brain Ischemia / complications*
  • Brain Ischemia / drug therapy*
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Female
  • Fibrinolytic Agents / administration & dosage
  • Fibrinolytic Agents / adverse effects*
  • Fibrinolytic Agents / therapeutic use*
  • Follow-Up Studies
  • Heparin / administration & dosage
  • Heparin / adverse effects*
  • Heparin / therapeutic use*
  • Humans
  • Intracranial Hemorrhages / etiology*
  • Male
  • Middle Aged
  • Outcome Assessment, Health Care
  • Prospective Studies
  • Risk Factors
  • Stroke / drug therapy*
  • Thrombolytic Therapy / adverse effects*
  • Time Factors
  • Tissue Plasminogen Activator / administration & dosage
  • Tissue Plasminogen Activator / adverse effects*
  • Tissue Plasminogen Activator / therapeutic use*

Substances

  • Fibrinolytic Agents
  • Heparin
  • Tissue Plasminogen Activator
  • Aspirin